Background: Leishmania is an intracellular protozoan parasite that uses complex methods for destroying the innate immune response in mammalian host macrophage cells. Many factors have been identified play a role severity of parasite’s pathogenicity. One GP63, which group metalloproteinases disrupts signaling mechanism cell. Objectives: The aim this study was to construct PX-LMGP63 vector throug...

Leishmaniasis, a spectrum of diseases caused by various forms of Leishmania has become a major health problem all over the world. Vaccination against leishmaniasis has passed through many developmental stages beginning with the ancient practice of 'leishmanization'. Due to various problems and difficulties associated with traditional vaccines, the interest has been shifted to novel approaches o...

Despite inducing very low IFN-γ response and highly attenuated in vivo, infection of mice with phosphoglycan (PG) deficient Leishmania major (lpg2-) induces protection against virulent L. major challenge. Here, we show that mice infected with lpg2- L. major generate Leishmania-specific memory T cells. However, in vitro and in vivo proliferation, IL-10 and IFN-γ production by lpg2- induced memor...

background: leishmania major lmsti1 is a conserved protein among different species of leishmania, and expressed in both amastigote and promastigote forms of l. major life cycle. it has previously been expressed in bacterial systems. m aterials and methods: to express lmsti1 in the methylotrophic yeast         pichia pastoris ( p. pastoris ), the shuttle vector ppicza containing gene lmsti1 was ...

Vaccination is the most effective method of preventing infectious diseases. Since the eradication of small pox in 1976, many other potentially life compromising if not threatening diseases have been dealt with subsequently. This event was a major leap not only in the scientific world already burdened with many diseases but also in the mindset of the common man who became more receptive to novel...

Vaccination with durable immunity is the main goal and fundamental to control leishmaniasis. To stimulate the immune response, small numbers of parasites are necessary to be presented in the mammalian host. Similar to natural course of infection, strategy using live vaccine is more attractive when compared to other approaches. Live vaccines present the whole spectrum of antigens to the host imm...

Leishmania vaccines that protect against needle challenge fail against the potency of a Leishmania-infected sand fly transmission. Here, we demonstrate that intradermal immunization of mice with 500 ng of the sand fly salivary recombinant protein LJM11 (rLJM11) from Lutzomyia longipalpis, in the absence of adjuvant, induces long-lasting immunity that results in ulcer-free protection against Lei...

Leishmaniasis affects 1.5-2 million new cases in the world annually. Two major complications of cutaneous leishamaniasis include diffuse cutaneous leishamaniasis (DCL ) occurring in the setting of deficient cell mediated immunity, typically with HIV infection, and chronic cutaneous leishamaniasis (CCL ) developing in approximately 4% of L. tropica infections in Iran and Afghanistan which also m...